{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Systemic+Sclerosis-associated+Interstitial+Lung+Disease", "query": { "condition": "Systemic Sclerosis-associated Interstitial Lung Disease" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 14, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Systemic+Sclerosis-associated+Interstitial+Lung+Disease&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-22T00:52:55.541Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05785624", "title": "A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Idiopathic Pulmonary Fibrosis", "Systemic Sclerosis With Lung Involvement" ], "interventions": [ { "name": "Vixarelimab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 286, "start_date": "2023-05-26", "completion_date": "2026-01-12", "has_results": false, "last_update_posted_date": "2026-02-09", "last_synced_at": "2026-07-22T00:52:55.541Z", "location_count": 28, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05785624" }, { "nct_id": "NCT01776398", "title": "Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chronic Obstructive Pulmonary Disease (COPD)", "Smoking", "Smoking Cessation", "Idiopathic Pulmonary Fibrosis (IPF)", "Rheumatoid Arthritis-Associated Interstitial Lung Disease", "Scleroderma-Associated Interstitial Lung Disease (SSC-ILD)" ], "interventions": [], "intervention_types": [], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2000, "start_date": "2012-08-29", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2025-11-14", "last_synced_at": "2026-07-22T00:52:55.541Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01776398" }, { "nct_id": "NCT05445817", "title": "Pulmonary Care and Research Collaborative Patient Registry", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Interstitial Lung Disease" ], "interventions": [], "intervention_types": [], "sponsor": "Pulmonary Care and Research Collaborative Limited", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2022-07", "completion_date": "2024-03", "has_results": false, "last_update_posted_date": "2022-07-19", "last_synced_at": "2026-07-22T00:52:55.541Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05445817" }, { "nct_id": "NCT03840928", "title": "PatientSpot Formerly Known as ArthritisPower", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Rheumatoid Arthritis", "Ankylosing Spondylitis", "Fibromyalgia", "Gout", "Crohn Disease", "Juvenile Idiopathic Arthritis", "Lupus Erythematosus", "Myositis", "Osteoarthritis", "Osteoporosis", "Psoriasis", "Psoriatic Arthritis", "Scleroderma", "Dermatomyositis", "Inflammatory Bowel Diseases", "Polymyositis", "Axial Spondyloarthritis", "Diffuse Idiopathic Skeletal Hyperostosis", "Polymyalgia Rheumatica", "Giant Cell Arteritis", "Temporal Arteritis", "Wegener", "Relapsing Polychondritis", "Undifferentiated Connective Tissue Disease", "Spinal Cord Injuries", "Alzheimer Disease", "Amyotrophic Lateral Sclerosis", "Ataxia", "Bell Palsy", "Brain Tumor", "Cerebral Aneurysm", "Epilepsy", "Guillain-Barre Syndrome", "Headache", "Head Injury", "Hydrocephalus", "Lumbar Disc Disease", "Meningitis", "Multiple Sclerosis", "Muscular Dystrophy", "Neurocutaneous Syndromes", "Parkinson Disease", "Stroke", "Cluster Headache", "Tension-Type Headache", "Chronic Obstructive Pulmonary Disease", "Asthma", "Lung Cancer", "Cystic Fibrosis", "Sleep Apnea", "Eczema", "Alopecia", "Chronic Inflammation", "Unstable Angina", "Heart Attack", "Heart Failure", "Arrythmia", "Valve Heart Disease", "High Blood Pressure", "Congenital Heart Disease", "Peripheral Arterial Disease", "Diabetes", "Chronic Liver Disease", "Obesity" ], "interventions": [], "intervention_types": [], "sponsor": "Global Healthy Living Foundation", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 40000, "start_date": "2015-04-01", "completion_date": "2025-03-01", "has_results": false, "last_update_posted_date": "2023-12-13", "last_synced_at": "2026-07-22T00:52:55.541Z", "location_count": 1, "location_summary": "Upper Nyack, New York", "locations": [ { "city": "Upper Nyack", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03840928" }, { "nct_id": "NCT02597933", "title": "A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Scleroderma, Systemic" ], "interventions": [ { "name": "Nintedanib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 580, "start_date": "2015-11-12", "completion_date": "2018-11-28", "has_results": true, "last_update_posted_date": "2019-12-13", "last_synced_at": "2026-07-22T00:52:55.541Z", "location_count": 44, "location_summary": "Birmingham, Alabama • Los Angeles, California • Sacramento, California + 36 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02597933" }, { "nct_id": "NCT02745145", "title": "Abituzumab in SSc-ILD", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Systemic Sclerosis-associated Interstitial Lung Disease" ], "interventions": [ { "name": "Abituzumab 1500 mg", "type": "DRUG" }, { "name": "Abituzumab 500 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 24, "start_date": "2016-05-31", "completion_date": "2018-05-30", "has_results": true, "last_update_posted_date": "2019-06-18", "last_synced_at": "2026-07-22T00:52:55.541Z", "location_count": 18, "location_summary": "Los Angeles, California • Farmington, Connecticut • Washington D.C., District of Columbia + 12 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Farmington", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02745145" }, { "nct_id": "NCT05455437", "title": "Monitoring and Evaluation Study of Project ECHO for ILD", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Interstitial Lung Diseases" ], "interventions": [], "intervention_types": [], "sponsor": "Pulmonary Care and Research Collaborative Limited", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 200, "start_date": "2022-07", "completion_date": "2024-03", "has_results": false, "last_update_posted_date": "2022-07-13", "last_synced_at": "2026-07-22T00:52:55.541Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05455437" }, { "nct_id": "NCT05450276", "title": "Patient-Reported Outcome Study of Project ECHO for ILD", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Interstitial Lung Disease" ], "interventions": [], "intervention_types": [], "sponsor": "Pulmonary Care and Research Collaborative Limited", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2022-07", "completion_date": "2024-03", "has_results": false, "last_update_posted_date": "2022-07-08", "last_synced_at": "2026-07-22T00:52:55.541Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05450276" }, { "nct_id": "NCT05270668", "title": "Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Cutaneous Systemic Sclerosis", "Interstitial Lung Disease" ], "interventions": [ { "name": "Tulisokibart", "type": "DRUG" }, { "name": "Companion diagnostic ( CDx)", "type": "DIAGNOSTIC_TEST" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 154, "start_date": "2022-03-29", "completion_date": "2029-07-31", "has_results": false, "last_update_posted_date": "2026-05-18", "last_synced_at": "2026-07-22T00:52:55.541Z", "location_count": 20, "location_summary": "Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 14 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05270668" }, { "nct_id": "NCT03726398", "title": "CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Interstitial Lung Disease", "Scleroderma", "Pulmonary Hypertension" ], "interventions": [ { "name": "Opsumit 10 Mg Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Franz Rischard, DO", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2018-09-01", "completion_date": "2020-08-03", "has_results": false, "last_update_posted_date": "2025-02-20", "last_synced_at": "2026-07-22T00:52:55.541Z", "location_count": 1, "location_summary": "Tucson, Arizona", "locations": [ { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03726398" } ] }